The Liver Medicine Market is expected to register a CAGR of 10.9% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Liver Medicine Market report covers analysis by Treatment Modality (Anti-viral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids); Disease Type (Hepatitis, Non- alcoholic fatty liver disease, Alcohol-induced liver disease, Liver Cancer); End-user (Hospitals, Specialty Clinics, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Liver Medicine Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Liver Medicine Market Segmentation
Treatment Modality- Anti-viral
- Vaccines
- Chemotherapy
- Immunosuppressive Agents
- Corticosteroids
- Hepatitis
- Non- alcoholic fatty liver disease
- Alcohol-induced liver disease
- Liver Cancer
- Hospitals
- Specialty Clinics
Strategic Insights
Liver Medicine Market Growth Drivers- Increased Prevalence of Liver Diseases: The increasing incidence of chronic hepatitis, cirrhosis, NAFLD, and other conditions that pose a threat to the liver makes the market for liver medicine. Other factors such as unhealthy dietary habits and high alcohol consumption are raising obesity rates globally. Increasing viral hepatitis cases are provoking rapid growth in liver diseases, which will require more treatment options to handle them.
- New Developments in Hepatitis Treatments: Global hepatitis eradication efforts have seen massive advancements in antiviral medication, particularly in hepatitis C. The discovery of direct-acting antivirals has made it easier to treat hepatitis C as more patients have high cure rates with minimal side effects. Such innovation has remained the primary force driving growth in the liver medicine market due to increasing demand for hepatitis treatment.
- Improving Awareness about Liver Health: Public awareness of liver health, as well as the risks of liver diseases, is helping the public become conscious and improve earlier diagnosis. As individuals become more alert to the potential risks of contracting liver disease, there is now a growing call for preventive treatment, such as vaccines for hepatitis, and therapeutic intervention.
- Personalized Medicine and Targeted Therapies: Personalized medicine is emerging in the liver medicine market. Treatments will be specially tailored to the patient according to genetic factors, disease progression, and biomarkers. Targeted therapies are primarily used in targeted treatments for specific molecular targets associated with liver diseases like liver cancer that have better effects with fewer side effects.
- Increasing Use of Combination Therapies: Combination therapies are increasingly being used, especially in chronic hepatitis C and liver cancer. The use of multiple drugs with different mechanisms of action can lead to improved treatment efficacy, a shorter treatment duration, and a reduced risk of drug resistance. This trend is likely to continue, especially as new therapies are developed.
- Increased Investment in Research on Liver Disease: The disease burden of such conditions is going up, but there is an investment in research conducted on liver diseases. Pharmaceutical firms, research houses, and governmental organizations invest in studies intended to identify new drug targets, biomarkers, and therapies for the treatment of this disease. Rising investment in research leads to new treatments and medical findings.
- Liver Cancer Drug Development: Liver cancer, particularly hepatocellular carcinoma (HCC), is among the most common types of cancers with a very high mortality rate. The ever-growing prevalence of liver cancer across the world is also leading to demand for new drugs. Immunotherapy, targeted therapy, and combination therapies are significant areas of research for the development of liver cancer drugs. Companies with the potential to introduce novel therapies in the market have a great opportunity to grow.
- Opportunities in the Vaccines Market: The hepatitis vaccine market has been growing steadily. Global efforts aimed at preventing liver diseases such as hepatitis B and C have kept the hepatitis vaccine market on the rise. Companies will have scopes to expand their vaccine offerings, particularly in regions where vaccination rates are still considered low. With more people seeking prevention against viral hepatitis, this will increase demand for vaccines.
- Biologics and Gene Therapies: Biologics and gene therapies are promising new treatment options for liver diseases, especially in chronic or advanced cases. Gene therapies targeting liver cells to correct genetic defects or alter disease pathways are an exciting area of research and development. Pharmaceutical companies are exploring the potential of biologics to treat liver diseases like cirrhosis and fibrosis, opening new market opportunities.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Liver Medicine Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Liver Medicine Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Liver Medicine Market are Increased Prevalence of Liver Diseases, New Developments in Hepatitis Treatments, and Improving Awareness about Liver Health
The key future trends of the market are Personalized Medicine and Targeted Therapies, Increasing Use of Combination Therapies, and Increased Investment in Research on Liver Disease
The leading players operating in the Liver Medicine Market include Gilead Sciences, Inc., Zydus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Abbott, Bayer AG.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Liver Medicine Market - By Treatment Modality
1.3.2 Liver Medicine Market - By Disease Type
1.3.3 Liver Medicine Market - By End-user
1.3.4 Liver Medicine Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LIVER MEDICINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LIVER MEDICINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LIVER MEDICINE MARKET - GLOBAL MARKET ANALYSIS
6.1. LIVER MEDICINE - GLOBAL MARKET OVERVIEW
6.2. LIVER MEDICINE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. LIVER MEDICINE MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT MODALITY
7.1. OVERVIEW
7.2. TREATMENT MODALITY MARKET FORECASTS AND ANALYSIS
7.3. ANTI-VIRAL
7.3.1. Overview
7.3.2. Anti-viral Market Forecast and Analysis
7.4. VACCINES
7.4.1. Overview
7.4.2. Vaccines Market Forecast and Analysis
7.5. CHEMOTHERAPY
7.5.1. Overview
7.5.2. Chemotherapy Market Forecast and Analysis
7.6. IMMUNOSUPPRESSIVE AGENTS
7.6.1. Overview
7.6.2. Immunosuppressive Agents Market Forecast and Analysis
7.7. CORTICOSTEROIDS
7.7.1. Overview
7.7.2. Corticosteroids Market Forecast and Analysis
8. LIVER MEDICINE MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
8.1. OVERVIEW
8.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
8.3. HEPATITIS
8.3.1. Overview
8.3.2. Hepatitis Market Forecast and Analysis
8.4. NON- ALCOHOLIC FATTY LIVER DISEASE
8.4.1. Overview
8.4.2. Non- alcoholic fatty liver disease Market Forecast and Analysis
8.5. ALCOHOL-INDUCED LIVER DISEASE
8.5.1. Overview
8.5.2. Alcohol-induced liver disease Market Forecast and Analysis
8.6. LIVER CANCER
8.6.1. Overview
8.6.2. Liver Cancer Market Forecast and Analysis
9. LIVER MEDICINE MARKET - REVENUE AND FORECASTS TO 2028 - END-USER
9.1. OVERVIEW
9.2. END-USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. SPECIALTY CLINICS
9.4.1. Overview
9.4.2. Specialty Clinics Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. LIVER MEDICINE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Liver Medicine Market Overview
10.1.2 North America Liver Medicine Market Forecasts and Analysis
10.1.3 North America Liver Medicine Market Forecasts and Analysis - By Treatment Modality
10.1.4 North America Liver Medicine Market Forecasts and Analysis - By Disease Type
10.1.5 North America Liver Medicine Market Forecasts and Analysis - By End-user
10.1.6 North America Liver Medicine Market Forecasts and Analysis - By Countries
10.1.6.1 United States Liver Medicine Market
10.1.6.1.1 United States Liver Medicine Market by Treatment Modality
10.1.6.1.2 United States Liver Medicine Market by Disease Type
10.1.6.1.3 United States Liver Medicine Market by End-user
10.1.6.2 Canada Liver Medicine Market
10.1.6.2.1 Canada Liver Medicine Market by Treatment Modality
10.1.6.2.2 Canada Liver Medicine Market by Disease Type
10.1.6.2.3 Canada Liver Medicine Market by End-user
10.1.6.3 Mexico Liver Medicine Market
10.1.6.3.1 Mexico Liver Medicine Market by Treatment Modality
10.1.6.3.2 Mexico Liver Medicine Market by Disease Type
10.1.6.3.3 Mexico Liver Medicine Market by End-user
10.2. EUROPE
10.2.1 Europe Liver Medicine Market Overview
10.2.2 Europe Liver Medicine Market Forecasts and Analysis
10.2.3 Europe Liver Medicine Market Forecasts and Analysis - By Treatment Modality
10.2.4 Europe Liver Medicine Market Forecasts and Analysis - By Disease Type
10.2.5 Europe Liver Medicine Market Forecasts and Analysis - By End-user
10.2.6 Europe Liver Medicine Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Liver Medicine Market
10.2.6.1.1 Germany Liver Medicine Market by Treatment Modality
10.2.6.1.2 Germany Liver Medicine Market by Disease Type
10.2.6.1.3 Germany Liver Medicine Market by End-user
10.2.6.2 France Liver Medicine Market
10.2.6.2.1 France Liver Medicine Market by Treatment Modality
10.2.6.2.2 France Liver Medicine Market by Disease Type
10.2.6.2.3 France Liver Medicine Market by End-user
10.2.6.3 Italy Liver Medicine Market
10.2.6.3.1 Italy Liver Medicine Market by Treatment Modality
10.2.6.3.2 Italy Liver Medicine Market by Disease Type
10.2.6.3.3 Italy Liver Medicine Market by End-user
10.2.6.4 Spain Liver Medicine Market
10.2.6.4.1 Spain Liver Medicine Market by Treatment Modality
10.2.6.4.2 Spain Liver Medicine Market by Disease Type
10.2.6.4.3 Spain Liver Medicine Market by End-user
10.2.6.5 United Kingdom Liver Medicine Market
10.2.6.5.1 United Kingdom Liver Medicine Market by Treatment Modality
10.2.6.5.2 United Kingdom Liver Medicine Market by Disease Type
10.2.6.5.3 United Kingdom Liver Medicine Market by End-user
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Liver Medicine Market Overview
10.3.2 Asia-Pacific Liver Medicine Market Forecasts and Analysis
10.3.3 Asia-Pacific Liver Medicine Market Forecasts and Analysis - By Treatment Modality
10.3.4 Asia-Pacific Liver Medicine Market Forecasts and Analysis - By Disease Type
10.3.5 Asia-Pacific Liver Medicine Market Forecasts and Analysis - By End-user
10.3.6 Asia-Pacific Liver Medicine Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Liver Medicine Market
10.3.6.1.1 Australia Liver Medicine Market by Treatment Modality
10.3.6.1.2 Australia Liver Medicine Market by Disease Type
10.3.6.1.3 Australia Liver Medicine Market by End-user
10.3.6.2 China Liver Medicine Market
10.3.6.2.1 China Liver Medicine Market by Treatment Modality
10.3.6.2.2 China Liver Medicine Market by Disease Type
10.3.6.2.3 China Liver Medicine Market by End-user
10.3.6.3 India Liver Medicine Market
10.3.6.3.1 India Liver Medicine Market by Treatment Modality
10.3.6.3.2 India Liver Medicine Market by Disease Type
10.3.6.3.3 India Liver Medicine Market by End-user
10.3.6.4 Japan Liver Medicine Market
10.3.6.4.1 Japan Liver Medicine Market by Treatment Modality
10.3.6.4.2 Japan Liver Medicine Market by Disease Type
10.3.6.4.3 Japan Liver Medicine Market by End-user
10.3.6.5 South Korea Liver Medicine Market
10.3.6.5.1 South Korea Liver Medicine Market by Treatment Modality
10.3.6.5.2 South Korea Liver Medicine Market by Disease Type
10.3.6.5.3 South Korea Liver Medicine Market by End-user
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Liver Medicine Market Overview
10.4.2 Middle East and Africa Liver Medicine Market Forecasts and Analysis
10.4.3 Middle East and Africa Liver Medicine Market Forecasts and Analysis - By Treatment Modality
10.4.4 Middle East and Africa Liver Medicine Market Forecasts and Analysis - By Disease Type
10.4.5 Middle East and Africa Liver Medicine Market Forecasts and Analysis - By End-user
10.4.6 Middle East and Africa Liver Medicine Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Liver Medicine Market
10.4.6.1.1 South Africa Liver Medicine Market by Treatment Modality
10.4.6.1.2 South Africa Liver Medicine Market by Disease Type
10.4.6.1.3 South Africa Liver Medicine Market by End-user
10.4.6.2 Saudi Arabia Liver Medicine Market
10.4.6.2.1 Saudi Arabia Liver Medicine Market by Treatment Modality
10.4.6.2.2 Saudi Arabia Liver Medicine Market by Disease Type
10.4.6.2.3 Saudi Arabia Liver Medicine Market by End-user
10.4.6.3 U.A.E Liver Medicine Market
10.4.6.3.1 U.A.E Liver Medicine Market by Treatment Modality
10.4.6.3.2 U.A.E Liver Medicine Market by Disease Type
10.4.6.3.3 U.A.E Liver Medicine Market by End-user
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Liver Medicine Market Overview
10.5.2 South and Central America Liver Medicine Market Forecasts and Analysis
10.5.3 South and Central America Liver Medicine Market Forecasts and Analysis - By Treatment Modality
10.5.4 South and Central America Liver Medicine Market Forecasts and Analysis - By Disease Type
10.5.5 South and Central America Liver Medicine Market Forecasts and Analysis - By End-user
10.5.6 South and Central America Liver Medicine Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Liver Medicine Market
10.5.6.1.1 Brazil Liver Medicine Market by Treatment Modality
10.5.6.1.2 Brazil Liver Medicine Market by Disease Type
10.5.6.1.3 Brazil Liver Medicine Market by End-user
10.5.6.2 Argentina Liver Medicine Market
10.5.6.2.1 Argentina Liver Medicine Market by Treatment Modality
10.5.6.2.2 Argentina Liver Medicine Market by Disease Type
10.5.6.2.3 Argentina Liver Medicine Market by End-user
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. LIVER MEDICINE MARKET, KEY COMPANY PROFILES
12.1. GILEAD SCIENCES, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ZYDUS PHARMACEUTICALS, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. TAKEDA PHARMACEUTICAL COMPANY LIMITED.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. NOVARTIS AG
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE LTD
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SANOFI
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ABBOTT
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BAYER AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. JOHNSON & JOHNSON PRIVATE LIMITED
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Gilead Sciences, Inc.
2. Zydus Pharmaceuticals, Inc.
3. Takeda Pharmaceutical Company Limited.
4. Novartis AG
5. Pfizer Inc.
6. F. Hoffmann-La Roche Ltd
7. Sanofi
8. Abbott
9. Bayer AG
10. Johnson & Johnson Private Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For